More than half of participants remitted after digital education about anxiety, while more than three-quarters remitted after ...

Emerging evidence highlights psilocybin as a potential therapy for treatment-resistant OCD, while cannabinoids show limited ...

You’ve surely heard of probiotics — but a budding class called “psychobiotics” is being touted for mental health benefits, with promises of improving mood, cognition and anxiety. Here’s what ...

Anxiety distorts perceptions of threat, magnifying worry. New findings suggest a diet tweak that can help sufferers.

Depression and anxiety are linked to a higher risk of heart attack, heart disease and stroke, and researchers now think they ...

A new clinical trial underway in the Lowcountry is drawing attention for its unconventional — and potentially groundbreaking ...

In a new paper published in NPP – Digital Psychiatry and Neuroscience, researchers argue that including scientists with lived ...

With a late-stage miss reported for its prospective social anxiety disorder (SAD) treatment fasedienol, Vistagen’s chances at ...

Investing.com -- Vistagen (NASDAQ:VTGN) stock plunged 78.8% Wednesday after the company announced its Phase 3 study of fasedienol for social anxiety disorder failed to meet its primary endpoint.

Fasedienol is a first-in-class pherine nasal spray that is designed to modulate the olfactory-limbic amygdala fear and anxiety neurocircuits.

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

The newly developed "Fellow Travelers in Treatment" scale highlights the importance of attending to social connections during ...